Eris Lifesciences Ltd (ERIS)

Eris Lifesciences Ltd (ERIS) is listed on the NSE in the Pharmaceuticals sector, Pharmaceuticals & Biotechnology industry. Market capitalisation: 19791.78 Cr. Figures below are as reported and are shown with their source and date.

Educational use only — GoQuant is a research tool. This page lists company facts only and is not a recommendation. Investment advice is provided by FINOME TECHNOLOGIES PVT LTD (AltQube), SEBI-registered Investment Adviser, registration no. INA000018373, under a signed advisory agreement and after a risk profile. Past performance is not indicative of future results.

Company profile

Sector
Pharmaceuticals
Industry
Pharmaceuticals & Biotechnology
Market cap (₹ Cr)
19,791.78

Eris Lifesciences Ltd. engages in the provision of pharmaceutical products. The company is headquartered in Ahmedabad, Gujarat. The company went IPO on 2017-06-29. The Company’s manufacturing plant is located in Guwahati, Assam. Its therapeutic areas include oral diabetes care, cardiac care, pain/analgesics, gynecology, gastrointestinal, central nervous system (CNS), and vitamins, minerals and nutrients (VMN). The firm's brands include Glimisave, Eritel, Renerve, Tendia, Olmin, Rabonik, Tayo, Cyblex, Lnbloc, Remylin, Zomelis, Crevast, Atorsave, Ginkocer and Metital. The Company’s wholly owned subsidiaries include Kinedex Healthcare Private Limited, Aprica Healthcare Limited and Eris Healthcare Private Limited.

Source: finedge · as of 2026-09-29

Price, last year

Last close (₹): 1,121.2

Source: quantro_screener_metrics_job · as of 2026-10-22

Key figures

P/E
25.07
52-week high
1,740
52-week low
1,111.1
Revenue CAGR, 3 years (%)
22.92
Revenue CAGR, 5 years (%)
20.89
EPS CAGR, 3 years (%)
16.75
EPS CAGR, 5 years (%)
11.32

Source: quantro_screener_metrics_job · as of 2026-10-23

Annual summary

Year endedRevenue (₹ Cr)PAT (₹ Cr)EPS (₹)
Mar 20263,129.42619.5244.72
Mar 20252,893.64351.8425.84
Mar 20242,009.14391.9828.82
Mar 20231,685.15382.1628.1
Mar 20221,347.04406.1129.88

Source: finedge · as of 2026-07-21

Shareholding and promoter pledge

Promoter
53.92%
FII
6.39%
DII
20.35%
Public
19.33%
Promoter shares pledged
16.91%

Source: finedge · as of 2026-03-31

Similar companies

Source: quantro_company_profiles · as of 2026-10-23

Frequently asked questions

What does Eris Lifesciences Ltd do?
Eris Lifesciences Ltd. engages in the provision of pharmaceutical products. The company is headquartered in Ahmedabad, Gujarat. The company went IPO on 2017-06-29. The Company’s manufacturing plant is located in Guwahati, Assam. Its therapeutic areas include oral diabetes care, cardiac care, pain/analgesics, gynecology, gastrointestinal, central nervous system (CNS), and vitamins, minerals and nutrients (VMN). The firm's brands include Glimisave, Eritel, Renerve, Tendia, Olmin, Rabonik, Tayo, Cyblex, Lnbloc, Remylin, Zomelis, Crevast, Atorsave, Ginkocer and Metital. The Company’s wholly owned subsidiaries include Kinedex Healthcare Private Limited, Aprica Healthcare Limited and Eris Healthcare Private Limited.
Which sector is Eris Lifesciences Ltd in?
Eris Lifesciences Ltd is in the Pharmaceuticals sector, Pharmaceuticals & Biotechnology industry.
What are Eris Lifesciences Ltd's latest annual revenue and profit?
For the year ended Mar 2026: revenue 3129.42 Cr, profit after tax 619.52 Cr.
What is the promoter holding and pledge in Eris Lifesciences Ltd?
Promoter holding is 53.92%; pledged shares are 16.91% of the promoter holding.
Which companies are similar to Eris Lifesciences Ltd?
Companies in the same sector of similar size: Onesource Specialty Pharma Ltd, Caplin Point Laboratories Ltd, Granules India Ltd, Pfizer Ltd, Cohance Lifesciences Ltd, Natco Pharma Ltd.
Want more history and detail? Create a free account for the full price history, quarterly statements, balance sheet and cash flow.

Figures computed 2026-10-23.